Under conditions of the contract, Abbott will develop a companion diagnostic test which will determine a patient’s genetic position and will be found in individual selection for future clinical trials of PF-02341066. Related StoriesSausages With Antioxidants From Berries To Prevent CancerOvarian cancer sufferers with a brief history of oral contraceptive use have better outcomesStudy shows uncommon HER2 missense mutations do not spread breast cancer by themselves’We are very pleased to partner with Abbott to build up a companion diagnostic test for non-little cell lung malignancy and assure its global availability for patients and physicians who need this information to make the greatest treatment decisions,’ stated Garry Nicholson, General Manager, Pfizer Oncology Business Unit.As a central component of its culture, Boehringer Ingelheim pledges to act responsible socially. Involvement in social projects, caring for employees and their own families, and providing equal opportunities for the building blocks is formed by all workers of the global procedures. Mutual respect and cooperation, along with environmental security and sustainability are intrinsic elements in all of Boehringer Ingelheim’s endeavors. This year 2010, Boehringer Ingelheim posted net sales around 12.6 billion euro while spending almost 24 percent of net product sales in its largest business segment Prescription Medications on research and advancement. 1. Stewart S, Murphy N, Walker A, et al. Price of an emerging epidemic: an economic evaluation of atrial fibrillation in the UK.